NCT04231877View on ClinicalTrials.gov

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2031

Conditions
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaT-Cell/Histiocyte-Rich Large B-Cell LymphomaGray-Zone Lymphoma
Interventions
DRUG

Polatuzumab Vedotin

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Prednisone

Given PO

DRUG

Etoposide

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Glofitamab

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

FDG-Positron Emission Tomography

Undergo FDG-PET scan

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Washington

OTHER

NCT04231877 - Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter